Actively Recruiting
Study of Anti-tumor T Cell Responses in Lung and Head and Neck Cancer Patients Receiving Concomitant Radiochemotherapy
Led by Centre Hospitalier Universitaire de Besancon · Updated on 2024-12-27
220
Participants Needed
4
Research Sites
495 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating how anti-tumor T cell responses change in adults with lung or head and neck cancer who receive combined radiochemotherapy as their initial treatment. The study focuses on understanding immune responses in patients undergoing this standard cancer therapy. Participants will receive first-line concomitant radiochemotherapy. During the study, blood and tumor tissue samples will be collected to analyze tumor antigen-specific T-cell responses. These immune responses will be monitored for up to 12 months after completing radiochemotherapy to assess modulation over time. Participants will be involved in providing biological samples and attending follow-up visits for immune response assessments. Researchers will track the tumor antigen-specific T-cell responses as the primary outcome, ensuring patients provide informed consent and meet eligibility criteria. The study includes ongoing monitoring during and after treatment to better understand immune changes related to the therapy.
CONDITIONS
Official Title
Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed non-small cell lung cancer, small cell lung cancer, or head and neck cancer
- Candidate for first-line concomitant radiochemotherapy
- Able and willing to provide written informed consent
You will not qualify if you...
- Previous sequential radiochemotherapy, exclusive radiotherapy, or stereotactic radiotherapy
- History of adjuvant radiochemotherapy for cancer treatment
- Current treatment with immunotherapy, chemotherapy, or immunosuppressive drugs except prednisone or prednisolone at 10 mg/day or less
- Known infection with HIV, hepatitis B, or hepatitis C virus
- Presence of any medical or psychiatric condition that could interfere with study participation
- Under legal guardianship, curatorship, or judicial protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
CHU de Besançon
Besançon, France, 25000
Actively Recruiting
2
Centre Georges François LECLERC
Dijon, France, 21000
Actively Recruiting
3
Hôpital Nord Franche-Comté
Montbéliard, France
Actively Recruiting
4
Institut Jean Godinot
Reims, France
Actively Recruiting
Research Team
O
Olivier ADOTEVI, Pr
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here